Akorn-Strides granted approval for seizure drug

Fosphenytoin Sodium Injection is a prodrug of Phenytoin Sodium and is indicated in the short term use for the prevention and control of generalized seizures occurring during neurosurgery.

Akorn-Strides is a joint venture that was formed in 2005 by Akorn and Strides Arcolab. The primary mission for the joint venture is developing liquid, lyophilized and dry powder fill generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.

Arthur Przybyl, president and CEO of Akorn, said: “We are excited to announce this product approval for Fosphenytoin Sodium Injection.”